VisCorp

Tianyin Pharmaceutical Co., Inc. (formerly Viscorp, Inc.) is a pharmaceutical company specializing in the development, manufacturing, and commercialization of modernized Traditional Chinese Medicine (TCM) and other pharmaceutical products in China. The company entered the life sciences sector in 2008 through a reverse merger between the US-based shell company Viscorp and Chengdu Tianyin Pharmaceutical. Its extensive portfolio includes over 30 marketed products, such as Azithromycin and various TCM formulations for chronic conditions like hepatitis and gastritis, many of which are listed in China's National Medicine Catalog. Historically, the company maintained a robust pipeline of over 50 products pending regulatory approval, supported by two GMP-certified manufacturing facilities and an R&D platform. Although previously listed on the NYSE MKT, the company was delisted in 2014 and transitioned to the over-the-counter market.